Canadian government moves to strengthen drug safety

14 November 2012

Canadian Minister of Health Leona Aglukkaq this week announced that Canada's Food and Drug Regulations will become even stronger, against a background of concerns relating to active pharmaceutical ingredients.

Currently in Canada, internationally accepted high quality standards, ie, Good Manufacturing Practices (GMP), are required for the production of pharmaceutical drugs. To make sure that the health and safety of Canadian consumers and their families are even more protected, the active ingredients (AI) in these drugs will be subject to these same standards.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical